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Abstract
Mechanisms of decreased endogenous vascular reactivity in individuals with cardiac syndrome X (CSX) are not fully
understood.
Aim.Toevaluatethefollowingserummarkers:totalnitricoxide(NO),asymmetricdimethylarginine(ADMA),platelet-derived
growth factor (PDGF), and to establish their relation to ultrasound indexes of endothelial function and structural remodeling
in CSX patients.
Method. The study group consisted of 43 CSX patients (mean age: 56.3 ± 9 years), while the control group included 21 healthy
subjects(meanage:54.86±6.9years).Thehigh-resolutionultrasoundwasperformedtomeasure:ﬂow-mediatedvasodilatation
(FMD), nitroglycerine-mediated vasodilatation (NMD) and intima-media thickness (IMT) of carotid arteries.
Results. In CSX patients, signiﬁcantly lower FMD (9.06 ± 3.2%) and signiﬁcantly higher IMT (0.667 ± 0.14 mm) values were
observed compared to healthy individuals (17.42 ± 8.4%, 0.571 ± 0.2 mm; P < 0.05). Mean total NO serum concentration
was signiﬁcantly higher in the CSX group (48.2 ± 18.2 mmol/L) as compared to controls (32.1 ± 1.4 mmol/L; P < 0.0001).
There were no differences in serum ADMA and PDGF levels. In CSX patients, FMD values correlated with NO (r = 0.323;
P = 0.039) and ADMA (r = -0.387; P = 0.012) serum levels; however, there were no signiﬁcant correlations between NO
and ADMA concentrations.
Conclusion. Serum ADMA concentration is the only independent factor determining FMD impairment.
Key words: Asymmetric dimethylarginine, cardiac syndrome X, ﬂow-mediated dilatation, nitric oxide, platelet-derived
growth factor
Introduction
Cardiac syndrome X (CSX) is usually regarded as a
combination of typical, anginal chest pain and posi-
tive exercise tolerance test (ETT), but neither ﬂow-
limiting stenoses nor spasm on coronary angiography.
A large body of evidence suggests its multifactorial
pathophysiology with prevailing mechanisms, includ-
ing subangiographic atherosclerosis, microvascular
ischemia, and abnormal sensitivity to visceral pain (1).
Literature data conﬁrmed impaired endothelial func-
tion in individuals with CSX (2,3). According to
some data the impairment of endothelial function
assessed by ﬂow-mediated dilatation (FMD) in CSX
patients may be even comparable to that observed in
patients with overt atherosclerosis, e.g. in coronary
artery disease (CAD). The degree of FMD impair-
ment may be important, as some authors suggest that
CSX patients with more exaggerated endothelial
dysfunction are characterized by a relatively worse
prognosis (4).
The mechanisms of decreased endogenous vascular
reactivity in individuals with CSX are not fully under-
stood. Hence, we followed our interest in potential
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markers of endothelial dysfunction or atherosclerosis
and ultrasound vascular indexes: FMD and intima-
media thickness (IMT).
The aim of our study was to evaluate the following
serum markers: total nitric oxide (NO; measured as
the stable end-product of NO, i.e. nitrite/nitrate),
asymmetric dimethylarginine (ADMA; an endoge-
nous competitive inhibitor of NO synthase), platelet-
derived growth factor (PDGF) and to establish their
relation to ultrasound indexes of endothelial function
and structural remodeling in CSX patients.
Material and methods
In total, 43 consecutive patients fulﬁlling the com-
monly recognized criteria for CSX (anginal chest pain,
positive ETT, and angiographically normal coro-
nary arteries) were included in the study (mean
age: 55.9 ± 9.3 years; female/male: 29/14). The
age- and sex-matched control group (mean age:
54.86 ± 6.9 years; female/male: 14/7) consisted of
21 healthy subjects without clinical evidence of
angina conﬁrmed in accessory investigations (ETT
and/or coronary angiography).
The exclusion criteria were: acute and chronic
inﬂammatory diseases (in 3 preceding months), ciga-
rette smoking within 12 h before examination, diabetes
mellitus, second and third degree of hypertension
according to European Society of Cardiology guide-
lines, history of myocarditis and vasculitis, spondy-
loarthritis, Tietze’s syndrome, gastrointestinal tract
diseases, diseases of the aorta, hormone replacement
therapy, arrhythmias that might disturb the multislice
computer tomography evaluation (atrial ﬁbrillation,
increased number of ventricular extrasystolic beats,
sinus tachycardia).
The clinical characteristics of patients consisted of:
medicalhistory(familialdiseases,concomitantdiseases,
pharmacotherapy used, and smoking status), physical
examination (arterial pressure, heartaction,bodymass,
and height, waist, and hip circumference), laboratory
tests (mainly lipidograms and fasting glucose), and
accessory investigations (electrocardiogram, echocardi-
ography, ultrasound vascular imaging) (Table I).
The diagnosis of hypertension was determined
based on blood pressure (BP) levels (systolic
BP ‡ 140 mmHg or diastolic BP ‡ 90 mmHg) or
report of a prior diagnosis of hypertension and current
antihypertensive treatment. In the study group, there
were30CSX patients(69.8%) withmildhypertension
TableI. Participant characteristics.
CSX (n = 43) Controls (n = 21) P
Mean ± SD or n (%) Mean ± SD or n (%)
Age (years) 55.9 ± 9.3 54.86 ± 6.9 NS
Female / male 29 (67.4%) / 14 (32.6%) 14 (66.7%) / 7 (33.3%) NS
Weight (kg) 82.1 ± 13.4 76.75 ± 14.7 NS
BMI (kg/m
2) 30.1 ± 4.4 28.83 ± 4.7 NS
WHR 0.88 ± 0.1 0.87 ± 0.1 NS
Waist (cm) 96.9 ± 10.6 91.23 ± 12.9 NS
Heart rate (bpm) 64.07 ± 9.3 66.92 ± 12.2 NS
SBP (mmHg) 139.44 ± 22.7 124.66 ± 14.2 NS
DBP (mmHg) 82.22 ± 12.5 76.00 ± 9.5 NS
Hypertension 30 (69.8%) 0 <0.001
Smoking status:
Current 3 (7.0%) 2 (9.5%) NS
Ex-smoker 17 (39.5%) 6 (28.6%) NS
Never smoked 23 (53.5%) 13 (61.9%) NS
TCh (mg%) 203.3 ± 46.7 199.02 ± 39.2 NS
TG (mg%) 143.6 ± 89.6 136.44 ± 104.3 NS
HDL (mg%) 63.7 ± 16.9 60.02 ± 9.4 NS
LDL (mg%) 113.0 ± 39.0 117.33 ± 32.2 NS
LVEF (%) 60.5 ± 6.1 62.8 ± 7.2 NS
LVMI (g/m
2) 128.0 ± 28.7 116.23 ± 26.7 NS
222 M. Haberka et al.(grade I), all of whom were treated with low or
mediumdosesofangiotensin-convertingenzymeinhi-
bitors (ACE-I).
Echocardiography was performed in all patients
according to the standards of the European Society
of Echocardiography. The values of left ventricular
ejection fraction (LVEF) and left ventricular mass
index (LVMI) were subjected to analysis.
All clinical data were obtained at the time of the
study. The measurements were performed after an
overnight fast and 12–24 hours without hypertension
medications and smoking.
The following vascular ultrasonography techniques
were used to assess the functional and structural
remodeling of the vascular system:
FMD–ﬂow-mediated dilatation
Endothelium-dependent ﬂow-mediated dilatation
(FMD) was assessed according to standard tech-
niques (5). Measurements of brachial artery FMD
were done in a quiet, temperature-controlled room,
between 9 and 11 a.m. Patients were examined after
at least a 10-minute rest; the ultrasound examination
was performed in a supine position. Expert investi-
gators took measurements in a B-mode presentation.
The brachial artery of the dominant forearm was
visualized above the antecubital fossa in a longitudinal
plane, with a sphygmomanometric cuff on the prox-
imal portion of the arm. The brachial artery diameter
was described as a minimal distance between ‘m’
lines, from the anterior to the posterior wall of the
artery. Images were acquired with an electrocardiog-
raphy gating, with measurements made in end dias-
tole, which corresponds to the onset of the R wave.
The study was performed in three stages: Stage 1)
base-line brachial artery diameter (BAd) and ﬂow
measurements were made, and an average was cal-
culated for each subject; Stage 2) the sphygmoma-
nometer cuff was inﬂated to 200 mmHg to occlude
arterial inﬂow for 3 minutes; and Stage 3) brachial
artery diameter and blood ﬂow were measured and
the mean calculated of the values obtained during
50–60 seconds after cuff deﬂation. Taking these two
measurements into consideration (base-line and
after cuff deﬂation), %FMD was calculated (percent
increase of the artery diameter in comparison to
base-lineresults).Aftera10-minuterest,asublingual
tablet of nitroglycerine (0.5 mg) was administered to
determine the maximum obtainable exogenous
vasodilatory response. Brachial artery diameter and
blood ﬂow were measured following nitroglycerine
(NTG),and%NMDwasdetermined(NTG-induced
percent increase of the artery diameter).
IMT–intima media thickness
Allmeasurementswereperformedinthecommonand
internal carotid arteries. The common and internal
carotids were studied in longitudinal planes with ante-
riorand lateral approaches. IMTwas measured within
the posterior wall of the artery. The average of ten
measurements was used to calculate IMT.
Expert investigators performed the echocardio-
graphy and the vascular ultrasound measurement
using a high-frequency ultrasound system (Toshiba
Aplio) equipped with a 3.5 MHz sector probe, a high-
frequency vascular transducer (multiple frequency:
7–10 MHz), and software for two-dimensional (2D)
imaging, color and spectral Doppler, an internal elec-
trocardiogram monitor.
Blood sampling and laboratory measurements
Blood sampleswere collected fromeachsubjectaftera
10-hourfast.Aftercentrifugation,aliquotswerefrozen
at -80 C until assayed.
The measurements of total NO/nitrite/nitrate were
performed with the total NO/nitrite/nitrate assay kit
(R&D Systems, Inc., Minneapolis, USA), based on
the enzymatic conversion of nitrate to nitrite by reduc-
tase, followed by colorimetric detection of nitrite
(Griess reaction). Human PDGF-BB measurements
were done with the use of enzyme-linked immu-
nosorbent assay (ELISA) kits (R&D Systems, Inc.).
The sensitivity of the total NO/nitrite/nitrate assay
was 0.25 mmol/L. Intra- and interassay coefﬁcients
of variation for total NO/nitrite/nitrate were <2.5%
and <4.6%, respectively. The sensitivity limit for
PDGF-BB was 15 pg/mL. The intra-assay coefﬁcient
of variation was <4.5%, and the interassay coefﬁcient
of variation was <7.6%.
The serum ADMA concentration was assessed
by the ADMA ELISA kit (Immundiagnostik AG,
Bensheim, Germany). The ADMA test disclosed
values as low as 0.05 mmol/L. The intra-assay coefﬁ-
cient of variation was <9.8%, and the interassay coef-
ﬁcient of variation was <7.5%.
Lipid parameters (serum cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides) were
measured using commercially available test kits (Point
Scientiﬁc Inc., Michigan, USA).
Statistical analysis
All text and table results are expressed as means ± SD
or number and percentage. The results were analyzed
with the ANOVA test, including the Newman-Keuls
correction. Clinical parameters and the results of
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chi-square test for proportions with the Yates correc-
tion, the two-sample t tests for normally distributed
continuous variable (Student’s t test); in case of
abnormal distribution, the Mann-Whitney U test was
used. Multivariable logistic and linear regressions
were used to assess independent predictors of the
FMD and IMT, respectively. A value P <0 . 0 5w a s
considered statistically signiﬁcant.
Results
Clinical characteristics
The clinical characteristics are set out in Table I.
Vascular parameters
Vascular indexes evaluation in cardiac syndrome X
patients revealed signiﬁcantly lower FMD (9.06 ±
3.2%) and signiﬁcantly higher IMT (0.667 ±
0.14 mm) values compared to healthy individuals
(17.42 ± 8.4%, 0.571 ± 0.2 mm; P < 0.05), whereas
brachial artery diameter (BAd) and nitroglycerine-
mediated vasodilatation (NTG-MD) were compara-
ble between both groups (Table II).
Biochemical markers
Among biochemical serum markers, only total NO
serum concentrations were signiﬁcantly higher in
the CSX group compared to the control group
(48.2 ±18.2 versus 32.1 ± 1.4 mmol/L; P < 0.0001),
while no signiﬁcant differences between both groups
were found in relation to ADMA (0.41 ± 0.08 versus
0.41 ± 0.13 mmol/L; P = 0.98) and PDGF (5193.62 ±
2530.1 versus 4716.95 ± 932.36 pg/mL; P = 0.368)
serum levels (Table II).
Correlation analysis
Inthe CSX group,total NO serum concentrationscor-
related signiﬁcantly with FMD (r = 0.323; P = 0.039)
and inversely with IMT (-0.354; P = 0.023) values.
Moreover, ADMA serum levels correlated signiﬁ-
cantly with IMT (0.384; P = 0.023) and inversely
with FMD (0.387; P = 0.012) values. Multivariate
regression analysis revealed the ADMA concentration
(t = -2.925; P = 0.007) and base-line brachial artery
ﬂow velocity (t = 3.965; P = 0.001) as independent
factors determining the FMD value (P = 0.001),
whereas PDGF serum concentrations were found to
correlate only with IMT values (r = 0.333; P = 0.038).
There were no associations between total NO,
ADMA, and PDGF concentrations.
Discussion
The body of evidence supports the hypothesis of
early functional and structural vascular changes in
the course of CSX. In our study, impaired vascular
indexes, including lower FMD and higher IMT, were
shown in the CSX group. Impaired FMD and
increased IMT constitute well evidenced markers of
earlyatherosclerosis andarecommonﬁndings inmost
CSX individuals observed in the previous studies (6–
8). It is of great importance that non-invasive ultra-
sound brachial artery FMD assessment is in close
relation to coronary artery endothelium-dependent
vasomotor responses to acetylcholine (9). Most stud-
ies showed that oral L-arginine administration is fol-
lowed by FMD improvement in CSX patients,
suggestinggeneralized endothelialdysfunctionrelated
to nitric oxide (NO) activity diminution (10–12).
However, there are studies providing conﬂicting
observations and showing preserved microcirculatory
endothelial function and impaired adenosine-medi-
ated endothelium-independent vasodilatation in CSX
patients (10).
In the present study, we assessed whether biochem-
ical markers may provide any new information to the
vascular indexes and the mechanism of vascular
abnormalities in CSX patients.
There are conﬂicting results in the literature on NO
and ADMA in CSX patients. Most studies conﬁrm
elevated ADMA and decreased NOx plasma levels
in the CSX population (1–18). ADMA plasma levels
were associated with impaired FMD (19), and recently
TableII. Results.
CSX (n = 43) Controls (n = 21) P
Mean ± SD Mean ± SD
BAd (mm) 4.00 ± 0.6 4.01 ± 0.5 NS
FMD (%) 9.06 ± 3.2 17.42 ± 8.4 0.008
NMD (%) 23.26 ± 13.4 24.95 ± 13.4 NS
IMT (mm) 0.67 ± 0.2 0.57 ± 0.2 0.021
ADMA
(mmol/L)
0.41 ± 0.08 0.41 ± 0.13 0.98
PDGF
(pg/mL)
5193.6 ± 2530.1 4716.9 ± 932.4 0.368
Total NO
(mmol/L)
48.2 ± 18.2 32.1 ± 1.4 <0.0001
range: 30.1–107.9 range: 30.3–34.2
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fusion was demonstrated (20). The results of our
study were not in accordance with the above-
mentioned data. We showed similar ADMA and
even increased NOx plasma levels in CSX patients
compared to normal controls. Plasma NOx levels
revealed a positive correlation with FMD and an
inverse association with IMT.
Regardless of the higher NO levels in CSX, the
FMD values were decreased as compared to controls.
It should be noted that NO analysis concerned the
base-line NO levels only. Thus we might conclude
only that base-line NO levels were higher in CSX as
compared to controls. At the same time, the FMD
marker of both shear-stress-induced NO release and
its bioavailability was impaired. The positive correla-
tion between basal NO level and FMD suggested that
in patients with higher base-line NO level the NO
releasewashigher.VascularresponsivenesstoNOwas
impaired and higher NO concentrations might have
contributed to the inappropriate adaptive mechanism.
Our confusing ﬁndings on NO levels might also be
related to the signiﬁcant presence of arterial hyper-
tension in the CSX group (30 patients; 69.8%) and
ACE-I treatment. Besides, increased concentrations
of NO levels might reﬂect an increased generation of
oxidants and augmented oxidative stress.
In the literature, there are few studies that do not
conﬁrm decreased NO levels in CSX subjects. Soysal
et al. showed substantially decreased NOx plasma
levels (20.2 mmol/L) in CAD patients, while similar
plasma levels (33.4 mmol/L versus 35 mmol/L) were
observed in CSX patients and normal controls (21).
In another study, Fragasso et al. found mildly
decreased NOx levels in CSX patients compared to
normal controls (24.2 mmol/L versus 26.8 mmol/L)
(22). Moreover, Desideri et al. did not demonstrate
impaired endothelial function in CSX patients in
terms of base-line plasma concentrations of NOx,
endothelin-1, and soluble vascular cell adhesion mol-
ecule 1 (VCAM-1) (23).
PDGF is another marker assessed in our study.
It plays a crucial role in the proliferation of different
cell types. Given that increased expressions of
PDGF and its receptors within atherosclerotic lesions
were observed, PDGF has been implicated in an
inﬂammatory-ﬁbroproliferative process. Furthermore,
PDGF has been demonstrated to have an angiogenic
effect, affect blood vessel tonus by inducing vascular
cell constriction, and on the other hand NO-mediated
relaxation and ﬁnally platelet aggregation (24). There
are lots of clinical trials on the role of PDGF in CAD
and its association with cardiovascular risk factors
(25–32). The data on PDGF in CSX are limited. In
our study, we found comparable PDGF plasma
concentrations between CSX patients and normal
controls. However, a signiﬁcant positive correlation
with IMT was demonstrated, which conﬁrms PDGF
association with vascular wall thickening.
The biochemical markers analyzed correlated with
ultrasound vascular indexes. We found the associa-
tions in terms of NOx and ADMA to both indexes,
and as mentioned above between PDGF and IMT.
However, among CSX patients, plasma ADMA con-
centrations were found to be an independent factor
determining only FMD values. It suggests the great
importance of ADMA in the pathophysiology of CSX.
Individuals with CSX have been assigned excellent
long-term prognoses. However, recent studies sug-
gest that the CSX population is not homogenous,
and a subpopulation with endothelial dysfunction
might be attributed a worse prognosis than previously
believed. Further observations of the CSX group
might explain the importance of lower FMD values
and the association with a new risk marker–ADMA
serum level.
There are some limitations of the study. The FMD
values are inﬂuenced by different factors as previ-
ously described (33). In order to avoid disturbances
in FMD evaluation we established the inclusion and
exclusion criteria and performed examinations in
optimal conditions. There are different methods of
NO serum level/bioavailability analysis. Therefore,
inconsistencies in study results might be partially
explained by different methodologies. Various cellular
sources of PDGF measured in human plasma must
be considered before ﬁnal conclusions are drawn.
Moreover,PDGFconcentrationsmeasuredinperiph-
eral circulation might differ from local plasma levels
in the coronary circulation (34). The role of PDGF
and its relation to atherosclerotic clinical complica-
tions still need to be clariﬁed. Finally, systemic arte-
rial hypertension, with a relatively high occurrence
in the study group of antihypertensive treatment
with ACE-I, might have affected the obtained levels
of biochemical parameters, including NOx plasma
concentrations. Although only patients with arterial
hypertension grade I were enrolled, as according to
the new CSX deﬁnition (1), the concomitance of left
ventricle hypertrophy and advanced hypertension
excludes a CSX diagnosis. The lack of LVMI differ-
ences between the CSX group and controls conﬁrms
our statement.
In summary, CSX patients were characterized by
early functional and structural markers of vascular
remodeling. Biochemical analysis revealed increased
serum NOx levels in this group as compared to
healthy subjects. Both the FMD index of endothelial
function and IMT correlated with biochemical mar-
kers of NO bioavailability. However, serum ADMA
Serum ADMA and nitrite measurement in CSX patients 225concentration was the only independent factor deter-
mining the FMD impairment. The above observa-
tions constitute a next step in better recognition of
CSX pathophysiology. Further studies are needed to
verify their clinical signiﬁcance.
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